The Guidelines highlight the measures States should undertake or refrain from undertaking in order to comply with their human rights obligations, while taking into account their concurrent obligations under the international drug control conventions.
This Guide conveys practical information as well as covering some theoretical advances to improve insights about the growing concern of methamphetamine use in Myanmar.
This manual is updated in the frames of “Harm Reduction Advocacy in Asia (HRAsia)”
project (2017-2019). The project is funded by The Global Fund to enable access to HIV and Harm
Reduction services for People Who Inject Drugs in Cambodia, India, Indonesia, Nepal, Philippines,
Thailand and Vietnam.
The purpose of this Technical Brief is to assist Global Fund applicants in their efforts to include and expand programs to remove human rights and gender-related barriers to HIV prevention, diagnosis and treatment services. This Brief discusses the barriers these programs help to remove, the various forms the programs take, the need to cost and allocate budget for them, and how to implement them in effective ways and at appropriate scale. It also aims to help stakeholders ensure that, as they are rolled out, HIV health services and programs promote and protect human rights and gender equality.
The tool describes how services can be designed and implemented to be accessible and acceptable to people who inject drugs. This requires respectful and ongoing engagement, and this publication gives particular attention to programmes run in close partnership with, or by, organizations of people who use drugs.
WHO updated its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014.
In this report, the International Drug Policy Consortium (IDPC) offers recommendations based on evidence and examples of good practice to inform a shift in policy responses to drug use in Asia away from criminalization and punishment, and towards public health and harm reduction. It describes effective approaches to the decriminalization of drug use. It also discusses approaches implemented in Asia that have proven ineffective, such as the detention of people who use drugs in compulsory centres as a form of ‘rehabilitation’.
In 2014, ANPUD has agreed to partner with HIV/ AIDS Asia Regional Program (HAARP) in supporting the meaningful involvement of people who use drugs (PWUD) in all areas of harm reduction policy and program implementation. This includes developing skills of people who use drugs in Lao PDR, Cambodia and Vietnam through the development and implementation of capacity building activities (including training modules) in consultation with country stakeholders.
The present document, “A Strategy to Halt and Reverse the HIV Epidemic among People Who Inject Drugs in Asia and the Pacific, 2010–2015” can be a crucial tool. It is a call to action and a road map to ensure that the HIV and hepatitis epidemics among people who use drugs and their sexual partners in the Asia Pacific region will be halted. The strategy is designed to provide a regional framework, and it identifies issues and priorities and provides guidance to countries in the region for developing national strategic responses over the next six years. It shows the important link between halting the HIV epidemic and health and development, and will help countries achieve United Nations Millennium Development Goal 6 that calls for a halt and a reverse in the spread of HIV by 2015.